ArticleNature2025
PPP2R1A mutations portend improved survival after cancer immunotherapy.
Erratum issuedAbstract read
In one paragraph
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Cadonilimab plus lenvatinib in advanced endometrial cancer: the multicenter single-arm phase II CLEAR-EC trial.Nature communications · 2026Trial
- Tertiary lymphoid structures in cancer: their development, composition, clinical prognosis, and the drivers of the anti-tumor responses.Molecular biomedicine · 2026Review
- Protein phosphatase 2A regulates senescence and immunogenicity in medulloblastoma models.The Journal of clinical investigation · 2026Article
- Advances in immunotherapies in ovarian cancer.Journal for immunotherapy of cancer · 2026Review
- CD4Science (New York, N.Y.) · 2026Article
- Article
- Immune Checkpoint Inhibitors and Immunomodulators for Cancer Immunotherapy: Insights Into Resistance and Therapeutic Strategies.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- The role of PPP2R1A variants in gynecologic malignancies: a paradigm shift in immuno-oncology.Journal of translational medicine · 2026Review
- Tumor cell intrinsic mechanisms of immune escape.Cell communication and signaling : CCS · 2026Review
- UniST: A Unified Computational Framework for 3D Spatial Transcriptomics Reconstruction.bioRxiv : the preprint server for biology · 2026Article
- Distinct immune microenvironments in ovarian cancer subtypes indicate potential for immunotherapies.Journal of translational medicine · 2026Article
- Investigating the molecular mechanisms of glutamine metabolism and mitochondria-related biomarkers in Alzheimer's disease through transcriptomics and experimental validation.European journal of medical research · 2026Article
- Spatial omics at the forefront: emerging technologies, analytical innovations, and clinical applications.Cancer cell · 2026Review
- PRECOG update: an augmented resource of clinical outcome associations with gene expression for adult, pediatric, and immunotherapy cohorts.Nucleic acids research · 2026Article
- Encapsulated Primary Human Ovarian Cancer Cells on Chips for Chemotherapy Drug Evaluation.Research (Washington, D.C.) · 2026Article
- Molecular profile and targeted therapies for ovarian clear cell ovarian cancer.Therapeutic advances in medical oncology · 2026Review
- Article
- Tumor Intrinsic METTL5 Modulates ATF4 Translation to Prevent T Cell-Induced Ferroptosis in Ovarian Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Soil and Seed: Tumor Microenvironment Nurtures Immunotherapy Resistance and Renewal.International journal of molecular sciences · 2025Review
- Targeting PP2A in cancer: an underrated option.Journal of experimental & clinical cancer research : CR · 2025Review
Corrections and comments
- Erratum issued
Authors and funding
41 authors.
Yibo Dai *Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Anne Knisely *Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mitsutake Yano *Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-4436-838X
Minghao Dang *Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-7287-2877
Emily M HinchcliffNorthwestern University, Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, Chicago, IL, USA.
Sanghoon LeeDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Annalyn WelpUniversity of Virginia School of Medicine, Charlottesville, VA, USA.ORCID 0000-0001-5888-3342
Manoj ChelvanambiDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-2130-3118
Matthew LastrapesDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-0780-3466
Heng LiuImmunology, Metastasis and Microenvironment Program, The Wistar Institute, Philadelphia, PA, USA.
Zhe YuanImmunology, Metastasis and Microenvironment Program, The Wistar Institute, Philadelphia, PA, USA.
Chen WangDepartment of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hao NieDepartment of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Stephanie JeanHelen F. Graham Cancer Center & Research Institute, Newark, DE, USA.
Luis J MontanerImmunology, Metastasis and Microenvironment Program, The Wistar Institute, Philadelphia, PA, USA.ORCID 0000-0001-5799-6759
Jiakai HouDepartment of Biology & Biochemistry, University of Houston, Houston, TX, USA.ORCID 0000-0003-2875-8756
Ami PatelDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shrina PatelDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Bryan FellmanDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ying YuanDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Baohua SunDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Renganayaki Krishna PandurenganDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Edwin Roger Parra CuentasDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Joseph CelestinoDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yan LiuDepartment of Anatomic Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jinsong LiuDepartment of Anatomic Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-3239-6658
R Tyler HillmanDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-9832-9925
Shannon N WestinDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-1922-0156
Anil K SoodDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-4242-1762
Pamela T SolimanDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Aaron ShaferDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Larissa A MeyerDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
David M GershensonDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
David ViningDepartment of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Dhakshinamoorthy GaneshanDepartment of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Karen LuDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jennifer A WargoDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-3438-7576
Weiyi PengDepartment of Biology & Biochemistry, University of Houston, Houston, TX, USA.ORCID 0000-0002-7785-6240
Rugang ZhangThe University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, Houston, TX, USA. RZhang11@mdanderson.org.ORCID 0000-0002-7255-2360
Linghua WangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. LWang22@mdanderson.org.ORCID 0000-0001-9380-0266
Amir A JazaeriThe University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, Houston, TX, USA. aajazaeri@mdanderson.org.ORCID 0000-0003-4335-4151
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8MTumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Aaron Robert Goldman · 1985 to 2026
$75.9MZACOPRIDE VS METOCLOPRAMIDE--EFFECT ON LOWER ESOPHAGEAL SPHINCTERM01RR000847 · NCRR · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI KRAMER, CHRISTOPHER M. · 1985 to 2010
$48.1MThe University of Texas MD Anderson Cancer Center SPORE in Ovarian CancerP50CA281701 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ROBERT C BAST, ANIL K SOOD · 2023 to 2026
$11.5MProject 3: Hedgehog Inhibition to Enhance Response to ICI TherapyP50CA272218 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FRANCESMARY MODUGNO · 2023 to 2026
$11.0MTraining of Academic Gynecologic OncologistsT32CA101642 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ANIL K SOOD, Kathleen Schmeler · 2005 to 2026
$9.2MCenter for Gastric Pre-Cancer Atlas of Multidimensional Evolution in 3D (GAME3D)U01CA294518 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Paul F Mansfield, Linghua Wang · 2024 to 2026
$5.4MMechanistic basis and therapeutic strategies for ARID1A mutation in ovarian cancerR01CA202919 · NCI · WISTAR INSTITUTE · PI Xi Chen, Rugang Zhang · 2016 to 2026
$4.1MTumor cell lineage diversity and composition in gastric cancer progression and therapy resistanceR01CA266280 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Pawel K. Mazur, Linghua Wang · 2022 to 2026
$3.2MRegulation of tumor recurrence by stress activated neutrophilsR01CA243142 · NCI · WISTAR INSTITUTE · PI ZHANG, RUGANG · 2020 to 2025
$2.8MSynthetic lethality based combination approaches to ARID1A mutation in ovarian cancerR01CA239128 · NCI · WISTAR INSTITUTE · PI ZHANG, RUGANG · 2019 to 2024
$2.5MSignaling basis of senescence-associated secretory phenotype and its implications in epithelial ovarian cancerR01CA276569 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Rugang Zhang · 2023 to 2026
$2.1MNCI NIH HHS K07 CA201013NCI NIH HHS L30 CA123720NCI NIH HHS P30 CA010815NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA272218NCI NIH HHS P50 CA281701NCI NIH HHS R01 CA202919NCI NIH HHS R01 CA239128NCI NIH HHS R01 CA243142NCI NIH HHS R01 CA260661NCI NIH HHS R01 CA266280NCI NIH HHS R01 CA276569NCI NIH HHS R01 CA306089NCI NIH HHS T32 CA101642NCI NIH HHS U01 CA294518NCRR NIH HHS M01 RR000847NIH HHS S10 OD024977
Abstract
Immune checkpoint blockade (ICB) therapy is effective against many cancers, although resistance remains a major issue and new strategies are needed to improve clinical outcomes
Indexed as
ImmunotherapyMutationNeoplasmsOvarian NeoplasmsProtein Phosphatase 2AnimalsCD8-Positive T-LymphocytesCell Line, TumorCohort StudiesFemaleHumansImmune Checkpoint InhibitorsInterferon-gammaMiceImmune Checkpoint InhibitorsInterferon-gammaPPP2R1A protein, humanProtein Phosphatase 2
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.